JP2016500088A - 即時放出および持続放出のための組成物 - Google Patents

即時放出および持続放出のための組成物 Download PDF

Info

Publication number
JP2016500088A
JP2016500088A JP2015543424A JP2015543424A JP2016500088A JP 2016500088 A JP2016500088 A JP 2016500088A JP 2015543424 A JP2015543424 A JP 2015543424A JP 2015543424 A JP2015543424 A JP 2015543424A JP 2016500088 A JP2016500088 A JP 2016500088A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
active ingredient
tolterodine
controlled release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015543424A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016500088A5 (enExample
Inventor
アフジャー，バリンダー
ヴァーマ，ラジャン
ヴィナヤクラオ バラブド，ウメシュ
ヴィナヤクラオ バラブド，ウメシュ
ハグステン，アルネ
ワナーバーガー，クリスティン
ブールグ，ランバブ
ヴィラスラオ サムワンシ，アモル
ヴィラスラオ サムワンシ，アモル
Original Assignee
フェリング ベスローテン フェンノートシャップ
フェリング ベスローテン フェンノートシャップ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フェリング ベスローテン フェンノートシャップ, フェリング ベスローテン フェンノートシャップ filed Critical フェリング ベスローテン フェンノートシャップ
Publication of JP2016500088A publication Critical patent/JP2016500088A/ja
Publication of JP2016500088A5 publication Critical patent/JP2016500088A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2015543424A 2012-11-21 2013-11-21 即時放出および持続放出のための組成物 Pending JP2016500088A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN3575DE2012 2012-11-21
IN3575/DEL/2012 2012-11-21
IN3947/DEL/2012 2012-12-20
IN3947DE2012 2012-12-20
PCT/EP2013/074373 WO2014079922A1 (en) 2012-11-21 2013-11-21 Composition for immediate and extended release

Publications (2)

Publication Number Publication Date
JP2016500088A true JP2016500088A (ja) 2016-01-07
JP2016500088A5 JP2016500088A5 (enExample) 2016-11-17

Family

ID=49619947

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015543424A Pending JP2016500088A (ja) 2012-11-21 2013-11-21 即時放出および持続放出のための組成物

Country Status (18)

Country Link
EP (1) EP2922525A1 (enExample)
JP (1) JP2016500088A (enExample)
KR (1) KR20150085826A (enExample)
CN (1) CN104797240A (enExample)
AR (1) AR093585A1 (enExample)
AU (1) AU2013349682A1 (enExample)
BR (1) BR112015011430A2 (enExample)
CA (1) CA2891365A1 (enExample)
EA (1) EA201590805A1 (enExample)
HK (1) HK1213779A1 (enExample)
IL (1) IL238648A0 (enExample)
IN (1) IN2015DN03984A (enExample)
MX (1) MX2015006399A (enExample)
PH (1) PH12015501096A1 (enExample)
SG (2) SG11201503913TA (enExample)
TW (1) TW201422254A (enExample)
WO (1) WO2014079922A1 (enExample)
ZA (1) ZA201503603B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105579057A (zh) 2013-07-23 2016-05-11 阿勒根公司 包含与β-3-肾上腺素能受体激动剂组合的去氨加压素的方法和组合物
KR20150144209A (ko) * 2014-06-16 2015-12-24 훼링 비.브이. 안정화된 데스모프레신 또는 이의 약학적으로 허용가능한 염을 함유 약학 조성물
CA2967390A1 (en) * 2014-11-20 2016-05-26 Allergan, Inc. Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist
EP3244881A4 (en) * 2015-01-12 2018-08-15 Nano Pharmaceutical Laboratories LLC Layered sustained-release microbeads and methods of making the same
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
KR20180054655A (ko) * 2015-09-01 2018-05-24 웰즐리 파마슈티컬스 엘엘씨 연장, 지연 및 즉시 방출 제형 제조 방법 및 용도
EP3355864A4 (en) * 2015-09-30 2019-05-22 Wellesley Pharmaceuticals, LLC COMPOSITION FOR REDUCING URINATION FREQUENCY, METHOD FOR THE PREPARATION AND USE THEREOF
AU2016331879A1 (en) * 2015-09-30 2018-05-17 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
TW201726114A (zh) * 2015-11-23 2017-08-01 魏斯理製藥公司 降低排尿頻率之組成物、其製備方法、及其應用
KR20180101403A (ko) * 2015-12-18 2018-09-12 웰즐리 파마슈티컬스 엘엘씨 배뇨 빈도 감소용 조성물, 제조 방법 및 용도
CA3018285C (en) 2016-04-21 2024-02-27 Valcuria Ab Composition and method for pretreating cancer
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
AU2018208531A1 (en) * 2017-01-11 2019-06-13 Ferring B.V. A fast disintegrating pharmaceutical composition
KR20190021180A (ko) * 2017-08-22 2019-03-05 아주대학교산학협력단 퇴행성 신경질환 치료용 복합 제형 조성물
CN117355296A (zh) * 2021-05-11 2024-01-05 阿德维斯尼公司 用于口服施用舒噻美的延长释放药物组合物
IL315049A (en) * 2024-08-15 2026-03-01 Prilenia Neurotherapeutics Ltd Taste-masked pridopidine formulations, method of use thereof and process for preparation thereof
US12389928B1 (en) * 2024-10-25 2025-08-19 Mccormick & Company, Inc. Flavor-changing product
CN120247191B (zh) * 2025-03-10 2026-06-19 天津大学 一种尿液废水防腐缓释产品及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003503341A (ja) * 1999-06-28 2003-01-28 サノフィ−サンテラボ 少なくとも一つの適時パルスを生ずる制御された放出用の医薬投与形態
JP2003517446A (ja) * 1998-11-11 2003-05-27 フアーマシア・アー・ベー 新規制御放出ビーズ、その製造方法、およびそれを含む多重ユニット製剤
JP2006502972A (ja) * 2002-05-07 2006-01-26 フェリング ベスローテン フェンノートシャップ デスモプレシンの口腔内分散性医薬製剤
WO2011120903A2 (en) * 2010-03-29 2011-10-06 Ferring B.V. A fast dissolving pharmaceutical composition
WO2011120904A2 (en) * 2010-03-29 2011-10-06 Ferring B.V. A fast dissolving pharmaceutical composition
US20120135050A1 (en) * 2010-07-08 2012-05-31 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4052997A (en) 1996-07-19 1998-02-10 Clarke-Garegg, Margaret A. Levan derivatives, their preparation, composition and applications including medical and food applications
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
CN100366294C (zh) 2004-04-30 2008-02-06 量子高科（北京）研究院有限公司 一种口腔速溶制剂及其生产方法
EP1629834A1 (en) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
WO2007029087A2 (en) 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Controlled release multiple unit formulations
US20090192228A1 (en) 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
KR20110075011A (ko) * 2008-11-10 2011-07-05 (주)아모레퍼시픽 서방성 미립자 및 이의 제조방법
WO2011013082A1 (en) * 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
MX356601B (es) * 2010-03-30 2018-05-29 Productos Maver S A De C V Combinación farmacéutica con efecto antimigrañoso, en presentación sólida de liberación diferenciada.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003517446A (ja) * 1998-11-11 2003-05-27 フアーマシア・アー・ベー 新規制御放出ビーズ、その製造方法、およびそれを含む多重ユニット製剤
JP2003503341A (ja) * 1999-06-28 2003-01-28 サノフィ−サンテラボ 少なくとも一つの適時パルスを生ずる制御された放出用の医薬投与形態
JP2006502972A (ja) * 2002-05-07 2006-01-26 フェリング ベスローテン フェンノートシャップ デスモプレシンの口腔内分散性医薬製剤
WO2011120903A2 (en) * 2010-03-29 2011-10-06 Ferring B.V. A fast dissolving pharmaceutical composition
WO2011120904A2 (en) * 2010-03-29 2011-10-06 Ferring B.V. A fast dissolving pharmaceutical composition
US20120135050A1 (en) * 2010-07-08 2012-05-31 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
INTERNATIONAL JOURNAL OF UROLOGY, vol. 17, JPN6017022936, 2010, pages 397 - 409, ISSN: 0003836028 *

Also Published As

Publication number Publication date
EP2922525A1 (en) 2015-09-30
CA2891365A1 (en) 2014-05-30
IL238648A0 (en) 2015-06-30
SG10201703388TA (en) 2017-05-30
EA201590805A1 (ru) 2015-11-30
SG11201503913TA (en) 2015-06-29
WO2014079922A1 (en) 2014-05-30
HK1213779A1 (zh) 2016-07-15
TW201422254A (zh) 2014-06-16
AU2013349682A1 (en) 2015-06-04
IN2015DN03984A (enExample) 2015-10-02
PH12015501096A1 (en) 2015-07-27
ZA201503603B (en) 2016-01-27
AR093585A1 (es) 2015-06-10
MX2015006399A (es) 2015-07-21
CN104797240A (zh) 2015-07-22
KR20150085826A (ko) 2015-07-24
BR112015011430A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
TW201422254A (zh) 用於速釋及延釋的組成物
US20150306170A1 (en) Composition for immediate and extended release
JP6174585B2 (ja) 速溶性医薬組成物
US10512695B2 (en) Fast dissolving pharmaceutical composition
JP5736031B2 (ja) 速溶解性医薬組成物
JP7042275B2 (ja) 速崩壊性医薬組成物
HK1181649B (en) A fast dissolving pharmaceutical composition

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160928

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170627

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180717